The Edit Health Review: It Tells You Which Pharmacy, Then Sells You Sleep

Sermorelin, and a sentence with no hedge in it

Here is the load-bearing claim on the sermorelin page, verbatim: "Sermorelin signals your body to release its own growth hormone, the way it did when you were younger. That signal fades with age. Restoring it supports deeper sleep, faster recovery, and lean muscle."

The first clause is true. Sermorelin is the 1-29 fragment of growth-hormone-releasing hormone, and it does prompt the pituitary to release GH. That is why it existed — largely as a diagnostic agent.

The sleep claim is particularly important here. Khorram’s 1997 study followed 19 older adults receiving a related GHRH analog: sleep quality was unchanged in both sexes, although lean body mass increased in men. That finding does not establish The Edit’s combined sleep, recovery and lean-muscle promise. ⁹ The older PubMed query was too narrow to support the claim that no adult body-composition or sleep outcomes had been measured. ⁵

A registry search can miss older published research or studies indexed under related chemical names. The relevant question is whether a study tested this preparation and these promised outcomes, not whether a particular query returned zero records.

The Edit presents all three benefits as effects of restoring the hormone signal. The small related-analog study does not establish that combination of outcomes for this preparation, particularly the sleep claim.

If you want the whole picture on growth-hormone-axis peptides rather than one company's product page, that is a compound question, and the evidence pages are where it belongs.

The copper cream, which has actually been tested

The GHK-Cu page is the most interesting product on the site, because unlike the others it makes a claim somebody has already run a randomized trial on.

The claim: "Applied topically, it supports firmer skin, smoother texture, and overall skin renewal." The benefit tiles are more specific still — "Softened fine lines: Texture can appear smoother over weeks of daily use." And, under who it is for, "Post-procedure recovery: supporting your skin after microneedling, laser, or peels."

That last one has a trial. In 2006, patients undergoing CO2 laser skin resurfacing were randomized to a post-treatment regimen with or without GHK-Cu skincare, with blinded evaluators and computer analysis of erythema, and a validated questionnaire before and twelve weeks after. Thirteen patients completed it. The finding, in the authors' own words: "Objective evaluation found no significant improvement in wrinkles or overall skin quality." What did differ was how satisfied patients said they were. ³

So the claim closest to being testable was tested, and the objective endpoints did not move. That is not the same as proof the product does nothing — thirteen patients is a very small trial, and a null result at that size is weak evidence. It is, however, the only randomized evidence there is, and it points the other way from the page.

The registry does not rescue it. As of August 2026, ClinicalTrials.gov lists three studies with GHK-Cu as an intervention. The highest-phase one, NCT07437586, is phase 2, recruiting, sixty participants estimated, and it studies a gel for acute skin wound healing — not a cream for fine lines. ⁴ It has produced no results. A third listing surfaces in a GHK-Cu search only because a hydrafacial device trial includes a GHK-bearing serum in one arm; it is a study of the device, not the peptide.

What the NAD+ research does not establish

The NAD+ preparation needs evidence beyond the molecule’s role in cellular metabolism.

The NAD+ page sells "steadier energy," "sharper focus," "clearer thinking without the caffeine swing," and "healthy aging" — delivered by subcutaneous injection, with a nasal spray listed as coming soon.

For the promised sharper focus, a metabolism study is not enough. A small 2019 trial tracked blood and urine metabolites during IV NAD+ infusion; it did not evaluate The Edit’s subcutaneous formulation or demonstrate clearer thinking. ¹⁰ The August randomized-trial query documented here should not be mistaken for a complete account of human research. ⁸

Studies of oral NAD+ precursors also concern different molecules and routes. They do not validate this injection. The glutathione skin studies cited here used oral or topical preparations, not The Edit’s injection. ^{6 7}

The one paragraph missing from every page

There is a sentence The Edit has already written, correctly, in plain language:

"Compounded medications are not FDA-approved. The FDA does not evaluate compounded products for safety, effectiveness, or quality."

It appears only in a behind-the-scenes file The Edit publishes for AI search tools.

It does not appear on the tirzepatide page, the semaglutide page, the sermorelin page, the NAD+ page, the glutathione page or the GHK-Cu page. Those pages carry a different line: "This treatment requires licensed provider review and approval," plus "Compounded" as a small label beside the product name. The help center gets closest, telling readers that compounded semaglutide and tirzepatide are "not affiliated with, endorsed by, or a substitute for" the branded products — true, and not the same statement.

A reader comparing treatments should be able to find that regulatory distinction on the product page. Its presence in a machine-readable file does not resolve the omission from the patient-facing pages reviewed.

What testing does and does not mean here

The Edit's testing disclosure is one line, in a rotating marquee on the home page: "Dispensed by The Pharmacy Hub, batch-tested for potency and sterility."

Both of the right things are named. Potency tells you the vial is the strength the label says; sterility tells you it is not contaminated. "Batch-tested" implies per-lot rather than periodic sampling, which is the stronger claim.

What is not published: which standard sterility is tested against, what potency tolerance is accepted, whether endotoxin or pH are tested at all, which laboratory does the work, and — the one a customer could actually use — a certificate of analysis for any lot. Sellers who publish a testing program and sellers who publish a lot report are making different claims, and this is the first kind.